Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives $18.00 Consensus Price Target from Analysts
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year target price […]
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year target price […]
